Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ThermoBreast

Financiado

Cerrado

An innovative non-contact and harmless screening modality set to change the cour...

An innovative non-contact and harmless screening modality set to change the course of breast cancer detection and patient monitoring Female breast cancer is the most diagnosed cancer worldwide. In 2020, the International Agency for Research on Cancer estimated more than 2.26 million new cases of breast cancer. Early detection is crucial to survival; recovery ra... ver más

31/12/2026

THERMOMIND LTD

11M€

Presupuesto del proyecto: 11M€

Líder del proyecto

THERMOMIND LTD No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 19 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-11-28

HORIZON-MISS-2021-CANCER-02-01: Develop new methods and technologie... ExpectedOutcome:Prevention is the most cost-effective long-term cancer control strategy. In EU-27 an...

I+D

Cerrada

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

19 Participantes

THERMOMIND LTD

3.64M€ | Lider

Assuta Medical Centers

531.99K€ | Participante

VUB

407.56K€ | Participante

INSTITUT GUSTAVE ROUSSY

571.37K€ | Participante

Proyectos interesantes

ThermoBreast

Medical Technol...

Data Science

11M€ Financiado

OE Scan

Medical Technol...

Data Science

71K€ Cerrado

EDOCALD

Medical Technol...

Data Science

2M€ Cerrado

PID2019-110686RB-I00

Medical Technol...

Data Science

81K€ Cerrado

EUIN2013-51009

Medical Technol...

Data Science

25K€ Cerrado

SISTEMAS DE DIAGNÓSTICO PRECOZ Y TRATAMIENTO...

Medical Technol...

Data Science

351K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 49 meses Fecha Inicio: 2022-11-28
Fecha Fin: 2026-12-31

Líder del proyecto

THERMOMIND LTD No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 11M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Female breast cancer is the most diagnosed cancer worldwide. In 2020, the International Agency for Research on Cancer estimated more than 2.26 million new cases of breast cancer. Early detection is crucial to survival; recovery rates approach 90% when detected in early stages. National population-based cancer screening programmes in Europe currently implement 3 standard imaging modalities: mammography, ultrasound and MRI. The downsides of these screening methods include ionising radiation, high costs and high false positive rates in screening results. Our multidisciplinary consortium of 16 partners from 10 countries aims to contribute to EU’s Mission on Cancer and Beating Cancer Plan by drastically improving the prevention, diagnosis and monitoring of breast cancer while reducing the burden on women and female patients and their families, health care professionals and others who are directly or indirectly affected by breast cancer. ThermoBreast proposes a new solution for accurate, harmless and non-contact screening, equally applicable for all age groups and breast densities and capable of detecting pre-cancerous states. This risk-free screening technology, recently patented by the project coordinator ThermoMind LTD, can detect vascular anomalies and asymmetry, caused by cancerous growth. It combines innovative screening through multiple sensitive infrared sensors with advanced AI analysis of temporal dynamic thermal patterns. Through its patient-centred integrated diagnostics approach, this project converges intelligent computer vision, blood vessel extraction and tissue analysis with advanced information technology to deliver a medical class 1 device that will be validated in an international multicentre clinical study. To enhance stakeholder participation, ThermoBreast involves end users, SSH experts and a patient organisation in the co-creation of the new screening solution and assesses its health and socio-economic benefits as well as its cost effectiveness. This action is part of the Cancer Mission cluster of projects on ‘Prevention, including Screening’.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores